Pharmaceutical Industry: Drug Interactions and Quality Control, Exams of Nursing

Download Pharmaceutical Industry: Drug Interactions and Quality Control and more Exams Nursing in PDF only on Docsity!

i cellsai ndipromote iwhite ibloodicelliproduction. … irequire i that i the i patient i first i undergo i chemotherapy i or i radiation i to ikill ithe i diseased istem

Napsrx Test Questions and Answers 2024

1. Howiare idrugsisortediintoitherapeuticigroupsiandiclasses? A. firstiby itheiconditionsithatithey iare iuseditoitreat,ianditheniby itheirimechanisms iofiaction B. firstibyitheirimechanismsiofiaction,ianditheniby itheiritherapeuticieffects C. firstibyitheirisideieffects,iandithenibyitherapeuticieffects D. firstibyitheiritoxically,iandithenibyitheirieffectiveness 2 i .Bone imarrow itransplants… A. B. …iareiaitypeiofistemicellitherapy,iunlessipatient’siownicellsiareireinjected. C. …iare ialwaysiaitypeiofistemicellitherapy. D. … ican i help ipeople iwith i leukemia, i a i condition iin iwhich i the ibody i does i not i produce i enough i whitebi loodicells.
2. WhatidoesiAMAistandifor? C.iAmericaniMedicaliAssociation
3. What i section i of i a i drug’s i package i insert i describes i situations i in i which i the i drug i should i not i be i usedibecause ithe irisks ioutweigh ithe itherapeuticibenefits? B. icontraindications i 5 .Whatiisitertiaryicare? B. i highly i specialized i medical i and i surgical i care i provided i by i a i large i medical i center i for i unusual i orci ompleximedical iproblems
4. Which iof ithe ifollowing iisiNOTione iof ithe istages iinithe iclassic iapproach ito ibrandidevelopmentistrategy ci overed iiniyourimanual? C. ibrandiquality
5. Whatiareivasodilatorsiuseditoido? A. B. mimicipathogensitoistimulateithe iimmuneisystem C. narrow itheibloodivessels D. stimulateithe iCNSitoimake itheiheartibeatifaster decreaseivasculariresistance iandiincreaseibloodiflow

8. What iis ithe iname iof ithe icondition ithat ioccurs iafter ia ispecific idose iof ia idrug iis igiven iat isuch iregular iintervals ithat iabsorption iand ielimination i(and itherefore idrug iplasma iconcentration) ihave ibecome iconstant? A. homeostasis B. C. titration D. tolerance
9. WhichistatementiisiTRUEiaboutioculariadministration? A. Oculariadministrationiisiprimarilyiforidrugsithatimusticrossithe iblood-brainibarrier. B. C. Oculariadministrationiisiusediwheniaidrugimustienterithe ibloodstreamiimmediately. D. Oculariadministrationiisiusediwheniaidrug imustiproduce iimmediate ieffectsionithe ibrainiorispinal icord.
10. Whichientity/entitiesiinvest(s)ithe imostimoneyiinipharmaceuticaliR&D? A. Canadianipharmaceuticalicompanies B. the iNIH C. theiU.S. iGovernment D. 1 i 1 .Howiare imostidrugsiexcreted? A. viaitheibloodstream B. viaitheiheart C. viaitheikidneys D. viaitheiskin
11. Overitheilastifew idecades,iwhatihasihappeneditoilegal ilimitations ion isales’irepsidiscussions iabout ioff ilabel iuses? A. Limitationsihaveidecreased. B. Limitationsihaveiincreasedisignificantly. C. Limitationsihaveiincreasedislightly. D. Limitationsihave iremainediaboutithe isame.
12. Accordingitoiyourimanual,iwhichiofitheifollowingiisianiexampleiofiaibrandingifundamental? U.S.ipharmaceuticalicompanies Oculariadministrationiisiusediprimarilyitoitreatitheieye.’ steadyistate

A. theibrandilogo B. theibrandiname C. theibrandipackaging D. theibrandipromise

14. Whatidoesiitimeaniifitwoidrugsiare iatiparity? A. Bothidrugsiare iessentiallyiiniaineutraliposition. B. Bothidrugsiare igenerics. C. Bothidrugsihaveiexclusiveipreferredistatus. D. Theitwoidrugsiare ibioequivalent.
15. Whoiisimostilikelyitoibenefitifromielectronicisamplingiprograms? A. Everyoneiwouldibenefitiequallyifromielectronicisamplingiprograms B. physiciansiinihospitalsiwhoiareitooibusyitoiseeirepresentatives C. physiciansiiniruraliareasiwhoiareinotiasifrequentlyivisitedibyirepresentatives D. physicians iin iurbaniareasiwho iare itoo ibusy ito isee irepresentatives i 16 .Whenireferringitoimedicationidosage,iwhichiabbreviationimeansi“one-half”: D. iSS
16. Whatiisianiinternist? A. iaiphysician iwhoipractices iinternal imedicine i 18 .Whichiofithe ifollowing iisiaitypeiofiwhiteibloodicells? C.ilymphocytes
17. WhyiareinoviceisalesirepresentativesiofteniplacediinichargeiofinegotiatingiMCOiformularies? A. toibecome imoreifamiliariwithithe ihealthcare iindustry B. toibecomeimoreifamiliariwithitheiriterritories C. P&Ticommitteesiareimoreireceptiveitoinewifaces. D. Theyiare inot. iThis ijobiisiusually ireservedifor imoreiexperienced ireps. 2 i 0 .Whatidistinguishes ipharmacodynamics ifromipharmacokinetics? A. Pharmacodynamicsistudiesiaidrug’siexivivoieffects. B. Pharmacodynamicsistudiesihowidrugsiaffectitheibody. C. Pharmacodynamicsistudiesitheibodyiaffectsidrugs.

D. Pharmacodynamicsistudiesitheitimeirequirediforiaidrug’siabsorption.

21. Whatiproportioniofithe idrugsitestedionihumanisubjectsiare ieventually iapprovediby iFDA? A. abouti20% B. abouti60% C. abouti70% D. abouti95%
22. According ito ia istudy i discussed iin iyour imanual, i how i do i most i physicians i prefer ito ireceive itheir idrugisamples? A. by iborrowingithemifromihospitals B. by iorderingithemioveritheiInternet C. by itradingithemiforiservices D. directlyifromisalesirepresentatives
23. Whichiofithe ifollowingiisianiexampleiofiaicentral ivalue? A. Iibuy iAdvilitoishowithatiI’mimoderniconsumer. B. I ilike iAdvilibecause iweiwereibothiborniinithei 80 s. C. IipreferiAdvilibecauseiIilikeitheiflavor. D. IipreferiAdvilibecauseiit’sieasieritoiswallow.
24. Whichiofithe ifollowing ispecialtiesilikelyihasithe iMOSTiemergencyicalls? A. cardiology B. psychiatry C. urology D. Allispecialistsihaveithe isameinumberiofiemergency icalls. 2 i 5 .Whatiaffectsithe irateiofiactive itransport? A. theiavailability ioficarriers,ibutinotienergy B. theiavailabilityiofienergy,ibutinoticarriers C. theiavailability ioficarriersiandienergy D. neitheritheiavailabilityioficarriers,inoritheiavailabilityienergy
25. Overitheilastifew idecades,iwhatihasihappeneditoitheiFDA iapproval itimeiforinew idrugs? A. Itihasibeenilengtheneditoiensureisaferidrug iproducts.

B. ItihasibeenilengtheneditoilimitiDTCimarketing. C. Itihasibeenishorteneditoiimproveidrugiquality. D. Itihasibeenishorteneditoireduce itheicostiofinew idrugidevelopment. 2 i 7 .Whichiof itheifollowingiwouldiNOTihelpiimproveicompliance? A. patientsilikingitheiriproviders B. patientsiusing ionlyioneipharmacist C. pharmacistsiunderstandingihowigenericsidifferifromibrandinamesidrugs D. supportigroups

28. Whichientityichooses iaidrug’sitradeiname? A. theidrug’siinventor B. theidrug’simanufacturer C. theiFDA D. theiUnitediStatesiPharmaceuticaliCouncil
29. Whatitypeiofistemicellsiare iobtainedifrom iembryosiandicanidevelopiintoiany icellitype? A. multipotent B. pluripotent C. totipotent D. Allistem icells icanidevelopiintoiany icell itype.
30. As i the i price i a i patient i pays i for i a i prescription i increases, i what i happens i to i the i likelihood i that i theipatient iwill ifill iit? A. Itidecreases. B. Itiincreases. C. Itiremainsiunaffectedibecauseitheiprescriptioniisineeded. D. Itiremainsiunaffectedibecauseitheiprescription’siincreasedicostiisioffsetibyiitsiperceivedivalue. 3 i 1 .Most iinvoluntary imovementsicomeifrom iwhichitype iofimuscle itissue? A. cardiaciandismooth B. onlyiskeletal C. skeletaliandicardiac D. skeletaliandismooth

32. Whichiofithe ifollowingiisiNOTione iofitheibody’simajoriorganisystems? A. theicardiovascularisystem B. theicellularisystem C. theigastrointestinalisystem D. theimusculoskeletalisystem
33. Howidoimostidrugsiexertitheiriprimaryiphysiologicalieffects? A. byiactivatingisynapsesibetweenidifferentitypesiofitissues B. by ibindingitoicellireceptorsithatiare isensitiveitoitheiripresence C. byiinhibitingisynapsesibetweenidifferentitypesiofitissues D. throughigeneticimutation
34. What i is i the i most i reliable i source i of i information i for i determining i therapeutically i equivalent i drugiproduct? A. AMAiguide B. BlueiBook C. FDA idrugilist D. OrangeiBook
35. Whatidoesisubcutaneousimean? C. ibeneathitheiouteriskin
36. Whatishouldiaisalesirepresentative idoiifiall iofithe iprimeispaces iiniaidrugicabinetiare icoccupied? A. askistaffiforipermissionitoimove isome iofitheiotheriproductsiinithe icabinet B. askistaffiforipermissionitoithrowiawayiexpirediproductsiinitheicabinet C. askithe idoctor iifihe istill ineedsisome iofithe iotheriproductsiinitheicabinet D. surreptitiouslyimoveiyourilargesticompetitor’siproductsioutiofitheiway
37. It i is i inappropriate i for i physicians’ i prescribing i behavior i to i be i educated i by i their i personal i tastes i andiidiosyncrasies A. True B. False
38. The iFDA idefinesiAPI iasithe iactive ingredientiiniaidrug,iwhichiproducesitheidesiredichange iin itheibody. A. pharmaceutical

B. positive C. potent D. primary

39. Whatiareithei 2 ilegaliclassifications ipfiwholesalers? A. distributors iandisupplyichains B. pharmacists iandiNAMs C. primaryiandisecondaryiwholesaleidistributors D. retailersiandiinstitutions
40. Whatitermidescribes itheiusageiofiaimedicationiforipurposesiother ithanitheiFDA-approvediindications oi n ithe ilabeling? A. contraindicativeiindication B. off-indicationiusage C. off-labeliusage D. secondaryiindication
41. Whatiisitheiacronymipharmacokinetics? C. iPK
42. Theidosage irangeiofiaidrugithatiisibothisafeiandibeneficialiknowniasithe itherapeuticiwindow. A. True B. False
43. Whatiisitypically iNOTiaicharacteristiciofiaipharmaceuticalisalesirep? A. Pharmaceuticalisalesirepsiareiauthenticiandireal B. Pharmaceuticalisalesirepsiareicreative C. Pharmaceuticalisalesirepiareifocused. D. Pharmaceuticalisalesirepiareinoticoncernediabouticompetitors.
44. Whatientityigrantsidrugipatents? A. theiFDA B. the iFDA iif ithe idrug iis iover-the-counter iand ithe iU.S. iPatentiand iTrademark iOffice iif ithe idrug iis iprescription C. the iFDA iofithe idrugiisiprescriptioniandithe iU.S. iPatent iand iTrademark iOffice iifithe idrugiisiover- ithe i-counter

D. theiU.S.iPatentiandiTrademarkiOffice

45. Which i of i the i following i refers i to i all i active i and i inert i pharmaceutical i ingredients i in i a i drug, i includingifillers iand icolors? A. formulation B. mycoplasma C. peptide D. saccharide
46. Whatiisitheidifferenceibetweenipotencyiandiefficacy? A. Doctorsipreferimoreipotentidrugs. B. Drugsimanufacturersipreferimoreipotentidrugs. C. Potencyirefersitoitheidrug’sieffectiveness,iwhileiefficacyirefersitoiitsistrength. D. Potencyirefersitoitheidrug’sistrength,iwhileiefficacyirefersitoiitsieffectiveness. i 47 .Whatiisithe iminimum ileveliofieducationirequirediforiainurseipractitioner? A. aicertificationiprogram B. aniassociate’sidegree C. aibachelor’s idegree D. aigraduate idegree
47. Howimany inames imustiaidrug ihave? A. atimostithree B. C. atimostifive D. atileastifive
48. Howihasiailonger idevelopmentitimeiincreaseditheicostiofibringingiainewidrug itoimarket? A. byidecreasingipatientiattrition B. by idecreasingitheicostioficapital C. byiincreasing itheicostioficapital D. by iincreasingitheinumberiofiproductirecalls
49. Senior icitizensiconsume iover timesiasimany ipharmaceuticals iasipeopleiunderi65. A. three atileastithree

B. five C. ten D. fifteen

51. Whatiagency iregulatesitheidistributioniandiuseiofinarcotics? A. DEA B. FTC C. OIG D. TSA
52. Whatiisipassive idiffusion? A. aitype iofipinocytosis B. membraneitransportiviaivesicles C. theiuse iofienergyitoihelpiaisubstanceipassifrom iailowiconcentrationigradientitoiaihighione D. when ia isubstance ifreely imovesithorough ia imembrane ifrom ia ihighiconcentration igradientito ia ilow ione
53. Whatiare itheiMAINicategories iofidrugsiunderiFDAijurisdiction? A. active idrugsiandiactive iplacebos B. biopharmaceuticalsiandinutraceuticals C. non-prescriptioniandinutraceuticals D. prescriptioniandinon-prescription
54. Whichiofithe ifollowingiisiainaturaliuterotoniciagent? A. hemoglobin B. leukotriene C. oxytocin D. VitaminiK
55. Whatiareiallimetabolites? A. activeisubstances B. inactiveisubstances C. injections D. productsiofimetabolism

56. Wheniaidrugiisiadministerediorally,iwhereidoesifirst-passimetabolismioccur? A. intestine B. liver C. pancreas D. stomach
57. Whatiisitheimedical itermiforiswelling? B. iedema
58. Whichiofithe ifollowing iisiNOTipartiofithe iSeven iStepiCascade iofiEmotion? A. be iaiconsultant,inotiairep B. identifyiwhatiyouriproductidoes C. reflect D. visualize itheipoweriofi 10
59. Whichipartiofiaiclinicaliresearchipaperiisifrequentlyireferreditoiasithe iroadimap? A. abstract B. findings C. letteritoitheieditor D. methods
60. Whichiofithe ifollowing iisiaimainiactive iingredientiinilungisurfactants? A. B. germicides C. sympathomimeticidrugs D. theophylline
61. Whatidoesiparenteralimean? B. iinjections
62. Whichitermidenotesiaitypeiofisubstance ithatienhances itheiactioniofiaidrug ioriantigen? A. adjuvant B. indicated C. ligase D. peptide animalilung iextract

63. Ifiaisales irepresentative’siproductiisiplacedionithe iseconditier iofistandardithree-tier iformulary,iwhich iof ithe ifollowing iisimostilikely itrue? A. itihasinotibeenireviewediby itheiP&Ticommittee. B. itiisiiniaineutralipositioniunless iitiisiatiparity iwith iotheridrugs. C. itiprobably ihasiexclusive ipreferredistatusiifiitinotiatiparity iwithianyiother idrugs. D. it iwill iessentially isell iitself iif iit iis igranted iexclusiveipreferred istatus. i 64 .WhichiofitheifollowingiisiNOTione iofitheifouribasicitransportimechanisms? A. activeitransport B. homeostasis C. passiveidiffusion D. pinocytosis
64. Whichistatementiaccurately idescribesiairelationshipibetweenidrugiagonistsiandiantagonists? A. Agonistsiandiantagonistsicanibeiuseditogether. B. Agonistsiandiantagonistsishouldinotibeiuseditogether. C. Antagonistidrugsiactivate ireceptors,iwhileiagonistsiblockiaccessitoireceptors. D. Antagonistsiareiendogenousiwhereasiagonistsiareiman-made.
65. Whatiisitheistudy iofithe ieffectsiandimovementiofidrugsiinithe ihumanibody? C.iclinicalipharmacology
66. According ito iyour imanual, iwhatiis ia icommon icomplaint ithat iphysicians ihave iabout itraditional isampling imethods? A. thatidrug isample isupply iisitooiunpredictable B. thatipatientsiare ilessilikelyitoitakeifreeisamplesibecauseithey ithinkitheyiareiloweriquality C. thatipatientsidoinotilikeiseeingidrugirepresentativesiinitheirioffices D. thatithey ireceiveitooimany idrugisamples
67. Which i of i these ientities iis iformed i by i two i or imore i hospitals i or iother i healthcare ientities i to i negotiateireducedirates iwith iitsiaggregated ipurchasing ipower? A. GPO B. In-stateiwholesaler C. PPO D. RPO

69. Whatiisianother inameiforiaidrug iderivediaibiologicicompound? A. B. oligonucleotide C. organism D. smallimolecule
70. What i is i the i most icommon i policy i regarding i pharmaceutical i reps i dispensing i drug i samples i in ihospitals? A. By ifederalilaw,idrugisamplingiisipermittediiniallihospitals. B. Byifederalilaw,iitiisiupitoiindividualiphysicians,inotitheihospital. C. Drugisampling iisiencouraged,ibutinotirequired. D. Drugisamplingiisiofteniforbidden.
71. Whichiofithe ifollowingiwouldihelpiyouibuilditrustiwithiaiphysician? A. askingiifiheiorishe iisihaving ianyiproblems iwithitheimanagedicareicoverageiofiyouriproducts B. repeatingiaiquestioniyouialreadyiasked C. surprisingithe ioffice istaffiwithiainew iposter iinitheibreakiroom D. Noneiofithese iwouldihelpiyouibuilditrustiwithiaiphysician.
72. What iterm idenotes ithe idifference ibetween ithe iusual ieffective idose iand idose ithat iinducesisevere ior ilife-threatening isideieffects? A. B. marginiofisafety C. theiplaceboieffect D. therapeuticiwindow
73. Whatiareiexcipients? A. a itype iof icell ireceptorito iwhich iantagonists ibindito idecrease ithe ieffects iof ithe ibody’s inatural iagonists B. anotheriterm igenericiequivalents C. sites iofiactionibesidesithe itargetisitesiofiaction D.
74. Whatiisianother itermiforitheiAWP? A. dock-to-dockiprice theiinertiingredientsiiniaidrugiformulation dose-responseirelationship largeimolecule

B. floatiprice C. D. non-stock iprice

75. Whichiofithese iisitheimostilikelyiuse iforiaiuterotoniciagent? A. B. toimakeithe iurineimoreialkaline C. toisupplementioralifoodiintake D. toitreatihyperthyroidism
76. AsiofiNovemberi 2013 ,iwhichiofitheseicountriesihasilegalizediDTC iadvertising iofiprescriptionidrugs? A. Canada B. Japan C. Spain D.
77. Whyiareioralidrugsioftenitakenioniemptyistomach? A. toibe imoreiwhollyiabsorbedibyistomach B. toiminimizeiabsorptionibyiintestine C. toiminimize inausea D. toipassithroughithe istomachimore iquickly
78. Whatiisioneifactorithatidifferentiatesicommunityihealthicentersifromihospitals? A. Communityihealthicenteriformulariesiareimoreirestrictive B. Communityihealthicentersihaveihigherireimbursementirates C. Neweribrandiname idrugsiare ieasieritoiaccessiaticommunity ihealthicenters. D. noneiof ithese
79. Howidoesisampling iprovideiaisocial ibenefit? A. Doctorsidonateitheiriunusedidrugisamplesitoicharities. B. Doctorsiofteniuseidrugsisamplesitoitreatipatientsiwhoiotherwiseicouldinotiaffordiit. C. Itiallowsipatientsitoitryioutidifferentiprescriptionimedicationsibeforeiconsultingiwithiphysicians. D. Drugisampling iprovidesiaisocialibenefitiiniall iofitheseiways.
80. Whichimedicalitermidenotesitheiuse iofiaistethoscope itoilisten itoithe iheart? noneiof ithese toiinduce ilabor listiprice

A. auscultation B. cardioversion C. catheterization D. echocardiography i 81 .Whatidoientericicoatingsido? A. facilitateivomiting B. helpidrugsidissolve iinistomach C. helpidrugsienteritheibloodstreamimoreiquickly D.

82. Whatiisitheidurationiofiexclusivityiforiorphanidrugs? A. 6 imonths B. 1 iyear C. 7 iyears D. 15 iyears
83. WhatidoiNationaliAccountiManagersido? A. actiasithe isales ireps’iprimary ipointioficontactiwithithe irestiofithe icorporation B. manageitheiFDAiapprovaliprocess C. negotiate icontractsiwithiMCOsiandiPBMs D. sell ionlyitoipharmacies
84. Whatidoesiitiusually imeaniifiaidrugirecall iisivoluntary? A. Pharmaciesimay ichooseiwhether itoireturnithe idrugioridispense iit. B. TheiFDAihasideterminedithatithe idrugiisiperfectlyisafe,ibutiineffective. C. The i manufacturer i has i recalled i the i product i on i its i own, i but i negotiated i with i the i FDA beforehand. D. Theimanufacturerihasirecallithe iproductiwithoutinegotiatingiwithitheiFDA. 8 i 5 .Whichiphaseiof iclinical itrials iisialsoiknowniasithe ipivotal iphase? A. Phase iI B. Phase iIII C. Phase iIV preventidissolutioniinitheistomach

D. Phase iIX

86. Duringiwhichiphase ioficlinical itrials iisitheinewidrug’sisafety iandieffectiveness ifirstitestediinithe itarget igroup? A. preclinical B. Phase iI C. Phase iII D. Phase i III i 87 .Howidoiantacidsiwork? A. by iincreasingibloodiflowitoithe istomach B. by iloweringigastricipH C. D. byisuppressingicholesteroliformationibyitheiliver
87. Whatiisioneiofitheibiggestitime iwastersiforiaipharmaceutical isalesirep? A. caterers B. pharmacists C. receptionists D.
88. Whatihappensiwheniequilibrium iisireached? A. equalinumbersiofimolecules icrossithe imembraneiinibothidirections B. moleculesistopimoving C. theiconcentrationigradientidecreasesiindefinitely D. the iconcentration igradientiincreasesiindefinitely i 90 .Whatiare itheimosticommonivectorsiusediinigeneitherapy? A. autologousiantigens B. liposomes C. nakediDNA D. viruses
89. Whatiisitheipercentageifee ithatitheidispenseripaysithe iwholesaleriforidistribution? A. marginifee travelitime byiraisingigastricipH

B. recharge C. standardifee D. upcharge

92. Whatiisitheidifferenceibetweeniaichronici(oricontinuing)ireaction,iandiaidelayedireaction? A. Chronicireactionsiareiexaggerated,iwhereasidelayedireactionsiareiidiosyncratic. B. Chronic i reactions ioccur i only iduring i treatment, iwhereas idelayed i reactions ionly i occur iduringiwithdrawal. C. Chronicireactionsipersistiforiailongitime,iwhereasidelayedireactionsitakeisomeitimeitoidevelop. D. Delayedireactionsiareialwaysiidiosyncratic,ibutichronicireactioninot. 9 i 3 .Whatiisiclinicalieffect? A. federallyifundediresearchicondition B. theieffectiofimaximumidosage C. D. theiuse iof itreatmentidrugs iin ichemotherapy i 94 .Whichiofitheifollowingiisianiexampleiofinoncompliance? A. aipatientiforgettingitoitakeiaidrug iatiaispecifieditime iaiday B. aipatientitaking iaidrug,ibutionlyibecause iitihasibeenicourt-mandated C. aipharmacistidispensingiaigenericiequivalentiofiaidrug iinsteadiofithe ibrandiname D. aiphysicianirefusing itoiprescribe iaidrugibecause i(s)he idoesinotitrustithe iclinical istudies ioniit 9 i 5 .Whatiisitheiaverage icirculationitime iofiblood? A. aboutiaiminute B. abouti 5 iminutes C. abouti 5 itoi 10 iminutes idependingionitheipatient’siage iandihealthiconditions D. abouti 10 iminutes
93. Whatiisioneiwayiiniwhichipharmaceuticalisellingiisidifferentifromiselling iinimostiotheriindustries? A. in i pharmaceutical i sales, i the i decisions-makers, i consumers, i and i payers i are i usually i the i same entity B. Pharmaceuticalisellingitakesilessitimeibecauseidoctorsiareisoibusy. C. RepresentativesidoiNOTisellithe iendiuseriofitheiproduct. D. RepresentativesiDOisellitoithe iendiuseriofithe iproduct. theiresponseiproducedibyiaimedication

97. From iwhatitypesiofientitiesidoiprimary iwholesaleidistributorsibuy imostiofitheir idrugs? A. brokerages B. buyingiclubs C. manufacturers D. physicians
98. WhatiisitheiOffice iofitheiInspector iGenerali(OIG)? A. aidepartmentiinipharmaceuticalicompanies B. C. aniarm iof itheiEuropeaniMedicinesiAgency D. aniarm iofithe iFDA
99. Whatiare idoctorsirequireditoiconsideriwhenideciding iwhetheriorinotiprescribe iaiparticular idrug? A. quantity iofilifeioveriquality iofilife B. thatinoidrugsiwithiadverse ieffectsishouldieveribeiused C. theiinferiorityiofiOTCidrugs D. theiseverityiofitheidisorderibeingitreatediandithe ieffectiitihasionithe ipatient’siqualityiofilife i 100 .Which ientityiassigns iainewidrugiits igenericinames? A. theidrug’siinventor B. TheiFoodiandiDrugiAdministration C. D. theiUnitediStatesiPharmaceuticaliCouncil
100. Drugsican ibe iused daysibeyonditheiriexpirationidate. A. 2 - 7 idays,idependingionithe imosticurrentimonograph B. 2 - 90 idays,idependingionistate ilaws C. 7 - 90 idays,idepending ionithe itypeiofidrug iandiitsitherapeuticiclass D. noneiof ithese
101. Whatiisinecessaryiforiaidrug itoibeiexcretediextensively iviaitheikidneys? A. Theidrugimustibeiwater-soluble,iandinotibinditooitightly itoiproteinsiinitheibloodstream. B. Theidrugimustihave iaiphospholipidibilayeriandibeinon-water-soluble. C. Theidrugimustihaveiaiphospholipidibilayer iandibindiwell itoiproteinsiinitheibloodstream. theiUnitediStates iAdoptediNameiCouncil aniarm iofithe iDepartmentiofiHealthiandiHumaniServices

D. Theidrugimustinotibeiwater-soluble.

103. Whichiorganizationioriindividual iinitiatesitheiclinical itrialiandifinances itheistudy? A. clinicaliresearchiorganization B. investigator C. researcher D. sponsor
104. The name idescribesitheiatomiciorimolecular istructure iofiaidrug. A. chemical B. generic C. pharmaceutical D. proprietary
105. Under i PhRMA i Code, i is i it i acceptable i or i unacceptable i for i a i pharmaceutical i sales i rep i to i take i aiphysicianiand itheiphysician’s ispouseito iaifundraising idinner? A. acceptable iifionlyitheiphysicianiattends B. acceptable iifionlyitheiphysicianiattends,iandithe itotal iisiunderi$ C. acceptable iifithe itotal iisiunderi$ D. unacceptable
106. The i Hatch-Waxman i Act i is i considered i the i most i significant i drug-related affecting i the ipharmaceutical iindustry isince i1962. A. experiment B. legislation C. process D. research
107. What i term i denotes i the iextent, i quality, i or i degree i to iwhich i a i substance i is i poisonous i or i harmful i toithe ibody? A. caliber B. chronicity C. indication D. toxicity
108. WhatiissueihasiMOSTiencouragediconsumers’idesireitoisee imoreiOTCimedications?

A. aiweakeripatients’irightsimovement B. lackiofiinsuranceicoverage C. lessireliance ionithe iInternet D. proliferationiofiherbaliremedies

109. Whatiisitheidegreeitoiwhichiaimedicationiproduces iaitherapeuticieffect? A. diffusion B. efficacy C. protease D. vector
110. Whatiisitheimostiimportantibenefitiofielectroniciprescribing? A. choice B. cost C. inquiries D. safety
111. WhenidoesitheiFDA iregulate igenericidrugs? A. onlyiifitheyiare ibrandedigenerics B. onlyiifitheyihaveibeenicontested C. always D. never
112. Whichiphaseiofitrialsilargely ideterminesitheiclinicalidose? A. preclinicalitrials B. Phase iIIitrials C. Phase iIII itrials D. Phase iIVitrials
113. Whatiisianiadvantageiofiinactivatedivaccinesioveriattenuatedivaccines? A. Inactivatedivaccinesiareilessiexpensiveitoiprepare. B. Inactivatedivaccinesihaveiaihigheriprobabilityiofieliciting itheidesirediimmunologicaliresponse. C. Inactivatedivaccinesihaveiaimoreistableishelfilife. D. Inactivatedivaccinesionlyirequireiaisingleidose.

114. Whichimedicalitermidenotesiailowisupply iofioxygenidue itoibloodiflow? A. potentiation B. ischemia C. TID D. titration
115. Whatiare itheitwoimainiofiprescriptionidrugimarketing? A. ( 1 ) imarketingitoiinsurance icompanies,iandi( 2 )imarketing itoipharmacies B. ( 1 ) iPBMimarketing,iandi( 2 ) imarketing itoigovernments C. ( 1 )iprofessionaliphysicianipromotions,iandi( 2 )idirect-to-consumeriadvertising D. ( 1 )ipublicly-fundedimarketing,iandi( 2 )iphysician-fundedimarketing i 116 .What iis itheisite iofidelivery iforisubcutaneousiinjections? A. fatty itissueibeneathithe isurface iofithe iskin B. lymphaticitissue C. muscle itissue D. theistomach,iviaia ispecial itypeiofineedle
116. Whatimustibe icontainediinithe iDescriptionisectioniofiaipharmaceutical ipackageiinsert? A. adverseieffects B. mechanism iofiaction C. pharmacokinetics D. theiproprietary inameiandiestablishediname
117. Whatiisitheistudy iofiaimediation’s ieffectsiasiitithroughithe ibody? A. pharmacodynamics B. pharmacogenetics C. pharmacogenomics D. pharmacokinetics
118. Customersipurchase iproductsifrom ipeopleitheyilike,itrust,iandirespect. i Thisiisicalledithe. A. closing iofithe isale B. firstitimeiadvantage C. likeabilityifactor

D. poweriofiknowledge

120. Whatiisipenicillin’simechanismiofiaction? A. Itidisturbsibacterialicelliwallisynthesis. B. Itiinhibitsitheiproductioniofiviruses. C. ItipreventsiproperiDNAireplication. D. Itisendsiaimessengeritoithe iboneimarrow itoiproduceiextraiwhite ibloodicells.
121. According ito iyour i manual, ihow ihas ithe iU.S. ihealthcare imarketplace ichanged iin ithe ilast ifew di ecades? A. FeweriandifeweriprescriptionidrugsihaveibeenimadeiavailableiasiOTCs. B. Managedicareihasibeeniincreasinglyireplacedibyimoreipatient-centerediapproaches. C. TheiagingiBabyiBoomerigenerationihasibegunidemanding imoreipersonalizediattention. D. There ihas ibeenidecreasediemphasis ion ipreventive ihealth. i 122 .Howidoesipharmaceuticalimarketingihelpinarrowitheitreatmentigap? A. Itiencouragesipatientsitoitakeimoreiactiveirolesiinitheirihealthcare. B. Itimakesidoctorsimoreiskepticaliofitheipharmaceuticaliindustry. C. Itimakesipatientsimoreiskepticaliofitheiridoctors’iopinions. D. all iofithose
122. Whatidoiimmunosuppressiveiagentsido? A. decreaseiriskiofiinfection B. increaseiriskiofiinfection C. increaseitheirisk iofirejectioniofiforeignibodies D. treatedipsoriasis
123. WhatitypesiofidrugsiareiEGFRiinhibitors? A. antineoplastics B. cardiovasculariagents C. CNSiagents D. mitoticiinhibitors
124. Whichiofithe ifollowing imeansioutside iofithe iliving ibody? A. enivivo

B. exivitro C. exivivo D. intraivivo

126. The i FDA i requirements i for i nutraceuticals i and i medicinal i herbs i are i just i as i stringent i as i for ipharmaceuticals. A. True B. False
127. What i is i the i estimated i net i gain i of i private-sector i healthcare’s i contributions i to i increased i U.S. i lifeei xpectancy? A. $5- 10 ibillion B. $40- 50 ibillion C. $800- 900 ibillion D. $2- 5 itrillion
128. WhichistatementiisiTRUEiregardingipost-approvalidrugimonitoring? A. Alliside ieffectsiareideterminediduringiclinicalitrials B. Drug i manufacturers i are i only i required i to i report i adverse i effects i if i they i are i severe i or i life-ithreatening. C. Drug imanufacturers i are i only i required i to i report i adverse ieffects i if i they ihave i been i proven i inci linicalistudies. D. TheiFDA icanichooseitoiwithdrawitheiriapprovaliifinewievidence iarises.
129. Which i term i denotes i when i tolerance i to i one i medication i causes i increased i tolerance i to i anotherimedication? A. cellitolerance B. cross-tolerance C. indicateditolerance D. minimizeditolerance
130. Patentsiexpire yearsifromithe idate iofifiling. A. ten B. fifteen C. twenty D. thirty

131. Afteriaitrade-nameidrug’sipatentiexpires,ihowimayigenericiversionsiofiitibeisold? A. onlyiunderitheibrandedigenericiname B. onlyiunderitheigenericiname C. onlyiunderitheioriginal itradeiname D. underitheioriginal itradeiname iorigenericiname
132. Whatiisirequirediforiainewipharmaceuticalitoibe iconsidered iaiviableitherapy? A. Iticauses inoiseriousiadverseieffects B. Iticausesinoisideieffects. C. Itihasianiactive iplacebo. D. It i is imore i effective i and/or i causes i fewer i serious i adverse i effects i than i other i drugs i on i the market.
133. UnderitheiAMAiguidelines,iwhoiisiultimatelyiresponsible iforiminimizing iconflicts iofiinterest? A. doctors B. lawyersiandiofficeimanagers C. pharmaceuticalicompanies D. salesirepresentatives
134. Theiactiofidispensingiaipharmaceutical ialternativeiforithe iproductiprescribediis. A. alternative ilicensure B. equivalenceipractice C. necessitatedisubstitution D. pharmaceuticalisubstitution
135. skipped
136. Whichiofitheifollowingiisitheicorrectimedicaliacronymiforieffectiveidose? A. DE B. ED C. EFD D. effiD
137. Whyiisioneigroupiofisubjectsigiven ianiactive idrug,iwhileianother igroupionlyireceivesiaiplacebo? A. toiassessipatients’iexpectations

B. toiassessitheidrug’sieffectiveness C. toiassessitheiprofessionalismiofitheistudyistaff D. toiassess itheisubjects’idemographics

138. A i generic i version i is i likely i to i have i some i inactive i ingredients i that i are i different i from i those i of i theioriginalidrug. A. True B. False
139. Whichiofithe ifollowing iisianiexample iofiaifunctional ivalue? A. I idrinkiCoca-Colaibecause iI iam iaicitizeniofithe iworld. B. IidrinkiCoca-ColaibecauseiIilikeilookingilikeiaitraditionalist. C. I idrinkiCoca-ColaibecauseiIilike itheitaste. D. I idrinkiCoca-Colaibecauseiitiisianiinternationalibrand. 1 i 40 .Whereiare imostidrugsimetabolized? A. interstitialispaces B. liver C. stomach D. theibloodstream
140. Whatiisiessentialitoitheiethicalirequirementithatisubjectsibe iselectedifairly? A. Selectionicriteriaishouldibeiwell-supportediby idocumentedievidence. B. Studies ishould imake ievery iattempt i to iconduct i research ion isubjects iwho iare iunderprivileged andiin ineediofimedical iattention. C. Subjectsishouldibe iselectedibasedioniscientificiobjectives. D. all iofithese
141. Which i of i the i following i is i the i most i appropriate i salutation i for i a i cover i letter i if i you i cannot i find i aicontact iname? A. DeariPersonneliDepartment B. DeariSirior iMadam, C. DeariSir, D. ToiWhomiItiMay iConcern,
142. Whatiisipartiofibecoming ianiindispensable ipharmaceutical isalesirep?

A. askingiforifeedback B. givingitheidoctorsianything itheyiaskiforitoiprescribeiyouriproducts C. keepingiyourimarketishare igoalsitheisameieachiterm D. notibotheringibusyidoctorsiinihospitals

144. Which iofithe ifollowing iis iNOT itypically iincluded iin ithe iindications iand iusage isection iof ithe ipackage iinsert iinformation? A. diseasesioriconditionsithatithe idrugsiisiapproveditoitreat B. theidrug’siactiveimetabolites C. theidrug’sirecommendediusualidosage D. theidrug’siusualidosageirange
145. Which iterm idenotes itheipractice ioficlassifying iphysicians iand iother ipotential iprescribers iby ai nticipated iprescriptionivolume? A. conditioning B. deciling C. detailing D. privateilabeling
146. Whatimakesiaidrugieligibleiforifastitrackiapprovalifromithe iFDA? A. Itiisiaigenericithat ihasialreadyibeeniapprovediasiaibrandedidrug. B. It iisiainew idrug. C. Itiisilessiexpensive ithaniwhatiisicurrently ionithe imarket. D. Ititreatsipatientsiwithiaiserious,ilife-threateningicondition.
147. Initheigastrointestinal itract, help ibreakiup itablets ito iensureifull ireleaseiof ithe iactive ipharmaceutical iingredient. A. binders B. disintegrants C. dispersingiagents D. lubricants
148. Accordingitoiyourimanual,iwhatidoesithe iPDRPido? A. Itieducatesipatientsionitheiritreatmentioptions. B. Itiexpandsisalesirepresentatives’iaccessitoipatientiinformation.